RVMD - REVOLUTION Medicines Inc Stock Price, Fair Value and News

46.43USD+0.87 (+1.91%)Market Closed

Market Summary

USD46.43+0.87

Market Closed

1.91%

RVMD Alerts

4 major insider sales recently.

RVMD Stock Price

View Fullscreen

RVMD RSI Chart

RVMD Valuation

Market Cap

7.7B

Price/Earnings (Trailing)

-15.82

Price/Sales (Trailing)

662.08

EV/EBITDA

-15.28

Price/Free Cashflow

-16.73

RVMD Price/Sales (Trailing)

RVMD Profitability

EBT Margin

-4212.40%

Return on Equity

-28.07%

Return on Assets

-25.38%

Free Cashflow Yield

-5.98%

RVMD Fundamentals

RVMD Revenue

Revenue (TTM)

11.6M

Rev. Growth (Yr)

-95.16%

RVMD Earnings

Earnings (TTM)

-484.3M

Earnings Growth (Yr)

-70.35%

Earnings Growth (Qtr)

28.19%

Breaking Down RVMD Revenue

Last 7 days

-1.1%

Last 30 days

17.2%

Last 90 days

26.6%

Trailing 12 Months

79.9%

How does RVMD drawdown profile look like?

RVMD Financial Health

Current Ratio

18.45

RVMD Investor Care

Shares Dilution (1Y)

55.19%

Diluted EPS (TTM)

-3.83

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	34.8M	29.5M	26.2M	11.6M
2022	26.8M	27.3M	29.5M	35.4M
2021	41.6M	40.2M	28.7M	29.4M
2020	48.4M	46.2M	46.3M	43.0M
2019	27.6M	35.1M	42.6M	50.0M
2018	0	0	0	20.2M

Get all data in R, Python etc through our Historical Stock Data APIs

About REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a tri-complex inhibitor of KRASG12C(ON) and KRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

CEO	Dr. Mark A. Goldsmith Ph.D.
WEBSITE	revmed.com
INDUSTRY	Biotechnology
EMPLOYEES	292

REVOLUTION Medicines Inc Frequently Asked Questions

What is the ticker symbol for REVOLUTION Medicines Inc? What does RVMD stand for in stocks?

RVMD is the stock ticker symbol of REVOLUTION Medicines Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of REVOLUTION Medicines Inc (RVMD)?

As of Thu Jul 25 2024, market cap of REVOLUTION Medicines Inc is 7.52 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RVMD stock?

You can check RVMD's fair value in chart for subscribers.

Is REVOLUTION Medicines Inc a good stock to buy?

The fair value guage provides a quick view whether RVMD is over valued or under valued. Whether REVOLUTION Medicines Inc is cheap or expensive depends on the assumptions which impact REVOLUTION Medicines Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RVMD.

What is REVOLUTION Medicines Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 25 2024, RVMD's PE ratio (Price to Earnings) is -15.52 and Price to Sales (PS) ratio is 662.08. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RVMD PE ratio will change depending on the future growth rate expectations of investors.